Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Malignant lymphoma. Pathology, diagnosis, therapy]

H Goldschmidt1, M Wallmeier, U Hegenbart

  • 1Medizinische Klinik und Poliklinik V, Universität Heidelberg.

Der Radiologe
|January 1, 1997
PubMed
Summary

Malignant lymphomas, including Hodgkin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322].

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow.

Journal of cancer research and clinical oncology·2019
Same author

[Erratum to: First-line treatment of multiple myeloma].

Der Internist·2019
Same author

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.

Journal of internal medicine·2019

Area of Science:

  • Hematology
  • Oncology
  • Medical Imaging

Context:

  • Malignant lymphomas encompass Hodgkin's disease and non-Hodgkin's lymphoma (NHL), requiring accurate staging for effective treatment.
  • Conventional therapies include polychemotherapy and radiotherapy, with diagnostic imaging significantly enhancing clinical staging accuracy.
  • Invasive pathological staging is now reserved for exceptional cases due to advancements in imaging techniques.

Purpose:

  • To review current therapeutic strategies for malignant lymphomas.
  • To highlight the role of diagnostic imaging in disease staging.
  • To discuss novel approaches like high-dose chemotherapy with stem-cell support and antibody-based therapies.

Summary:

  • Accurate staging, aided by advanced imaging (CT, MRI, ultrasonography), is crucial for therapeutic decisions in malignant lymphomas.
  • High-dose chemotherapy with autologous hematopoietic stem-cell support shows promise for relapsed high-grade NHL, with ongoing studies evaluating its primary role.
  • Experimental antibody therapies and sensitive methods for assessing treatment response are areas of future research.

Impact:

  • Improved accuracy in staging malignant lymphomas, reducing the need for invasive procedures.
  • Enhanced survival rates for patients with relapsed high-grade non-Hodgkin's lymphoma through novel therapeutic approaches.
  • Paving the way for future research into targeted therapies and non-invasive monitoring of lymphoma treatment efficacy.

Related Experiment Videos